Advanced search
Publication Cover
Progress in Palliative Care
Science and the Art of Caring
Volume 25, 2017 - Issue 3
Submit an article Journal homepage
95
Views
1
CrossRef citations to date
0
Altmetric
Articles

Dyspnea-alleviating and survival-prolonging effects of corticosteroids in patients with terminal cancer

Tsuyoshi MaedaDepartment of Pharmacy, Kasugai Municipal Hospital, 1-1-1 Takaki-cho, Kasugai, Aichi486-8510, JapanCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0001-6825-6131
ORCID Icon &
Toru HayakawaDepartment of Pharmacotherapy, Hokkaido Pharmaceutical University School of Pharmacy, 7-15-4-1 Maeda, Teine, Sapporo, Hokkaido006-8590, Japan
Pages 117-120 | Published online: 22 Feb 2017

References

  • Guirimand F, Sahut d'izarn M, Laporte L, Francillard M, Richard JF, Aegerter P. Sequential occurrence of dyspnea at the end of life in palliative care, according to the underlying cancer. Cancer Med 2015;4:532–9. doi: 10.1002/cam4.419
  • Gripp S, Moeller S, Bölke E, Schmitt G, Matuschek C, Asgari S, et al. Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. J Clin Oncol 2007;25:3313–20. doi: 10.1200/JCO.2006.10.5411
  • Maltoni M, Pirovano M, Scarpi E, Marinari M, Indelli M, Arnoldi E, et al. Prediction of survival of patients terminally ill with cancer. Results of an Italian prospective multicentric study. Cancer 1995;75:2613–22. doi: 10.1002/1097-0142(19950515)75:10<2613::AID-CNCR2820751032>3.0.CO;2-1
  • Vigano A, Donaldson N, Higginson IJ, Bruera E, Mahmud S, Suarez-Almazor M. Quality of life and survival prediction in terminal cancer patients. Cancer 2004;101:1090–98. doi: 10.1002/cncr.20472
  • Toscani P, Brunelli C, Miccinesi G, Costantini M, Gallucci M, Tamburini M, et al. Predicting survival in terminal cancer patients: clinical observation or quality-of-life evaluation? Palliat Med 2005;19:220–7. doi: 10.1191/0269216305pm1000oa
  • Mercadante S, Valle A, Porzio G, Aielli F, Adile C, Casuccio A, Home Care–Italy Group. Prognostic factors of survival in patients with advanced cancer admitted to home care. J Pain Symptom Manage 2013;45:56–62. doi: 10.1016/j.jpainsymman.2011.12.288
  • Mercadante S, Masedu F, Valenti M, Mercadante A, Aielli F. The characteristics of advanced cancer patients followed at home, but admitted to the hospital for the last days of life. Intern Emerg Med 2016;11:713–8. doi: 10.1007/s11739-016-1402-1
  • Currow DC, Smith J, Davidson PM, Newton PJ, Agar MR, Abernethy AP. Do the trajectories of dyspnea differ in prevalence and intensity by diagnosis at the end of life? A consecutive cohort study. J Pain Symptom Manage 2010;39:680–90. doi: 10.1016/j.jpainsymman.2009.09.017
  • Morita T, Tsunoda J, Inoue S, Chihara S. Survival prediction of terminally ill cancer patients by clinical symptoms: development of a simple indicator. Jpn J Clin Oncol 1999;29:156–9. doi: 10.1093/jjco/29.3.156
  • Bruera E, Neumann CM. Management of specific symptom complexes in patients receiving palliative care. CMAJ 1998;158:1717–26.
  • Gamborg H, Riis J, Christrup L, Krantz T. Effect of intraoral and subcutaneous morphine on dyspnea at rest in terminal patients with primary lung cancer or lung metastases. J Opioid Manag 2013;9:269–74.
  • Hui D, Xu A, Frisbee-Hume S, Chisholm G, Morgado M, Reddy S, et al. Effects of prophylactic subcutaneous fentanyl on exercise-induced breakthrough dyspnea in cancer patients: a preliminary double-blind, randomized, controlled trial. J Pain Symptom Manage 2014;47:209–17. doi: 10.1016/j.jpainsymman.2013.03.017
  • Matsuo N, Morita T, Iwase S. Efficacy and undesirable effects of corticosteroid therapy experienced by palliative care specialists in Japan: a nationwide survey. J Palliat Med 2011;14:840–5. doi: 10.1089/jpm.2011.0002
  • Tiep B, Carter R, Zachariah F, Williams AC, Horak D, Barnett M, et al. Oxygen for end-of-life lung cancer care: managing dyspnea and hypoxemia. Expert Rev Respir Med 2013;7:479–90. doi: 10.1586/17476348.2013.816565
  • Thomas JR, von Gunten CF. Clinical management of dyspnoea. Lancet Oncol 2002;3:223–8. doi: 10.1016/S1470-2045(02)00713-1
  • Ripamonti C. Management of dyspnea in advanced cancer patients. Support Care Cancer 1999;7:233–43. doi: 10.1007/s005200050255
  • Miyashita M, Matoba K, Sasahara T, Kizawa Y, Maruguchi M, Abe M, et al. Reliability and validity of the Japanese version of the Support Team Assessment Schedule (STAS-J). Palliat Support Care 2004;2:379–85.
  • Shionogi & Co., Ltd. Rinderon® (pharmaceutical interview form). Osaka: Shionogi & Co., Ltd .; 2013.
  • MSD Kabushiki Kaisha. Decadron® (pharmaceutical interview form). Tokyo: MSD Kabushiki Kaisha ; 2011.
  • Fuji Pharma Co., Ltd. Dexart® (pharmaceutical interview form). Toyama: Fuji Pharma Co., Ltd.; 2015.
  • Shionogi Co., Ltd. Predonine® (pharmaceutical interview form). Osaka: Shionogi & Co., Ltd.;2015.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.